Biopharmaceutical company AbbVie, Inc. (NYSE: ABBV) announced first-quarter 2025 financial results, reporting an increase in revenue and adjusted earnings. The company reported worldwide net revenues of $13.3 billion for the March quarter, up 8% from the corresponding period of 2024. The main operating segments registered growth. Net income, adjusted for special items, rose to $2.46 […]
“Biopharmaceutical company AbbVie, Inc. (NYSE: ABBV) announced first-quarter 2025 financial results, reporting an increase in revenue and adjusted earnings. The company reported worldwide net revenues of $13.3 billion for the March quarter, up 8% from the corresponding period of 2024. The main operating segments registered growth. Net income, adjusted for special items, rose to $2.46 […]
· April 25, 2025
Biopharmaceutical company AbbVie, Inc. (NYSE: ABBV) announced first-quarter 2025 financial results, reporting an increase in revenue and adjusted earnings.
The company reported worldwide net revenues of $13.3 billion for the March quarter, up 8% from the corresponding period of 2024. The main operating segments registered growth.
Net income, adjusted for special items, rose to $2.46 per share in Q1 from $2.31 per share in the year-ago quarter, exceeding estimates. On a reported basis, net income was $1.29 billion or $0.72 per share in the first quarter, compared to $1.37 billion or $0.77 per share last year.
